Cystic Fibrosis |
CF; Cystic Fibrosis Research Directions; Fibrocystic Disease of Pancreas; Mucoviscidosis |
Clinical Trial: Study of Total Energy Expenditure in Infants and Children With Moderate to Severe Cystic Fibrosis
This study is currently recruiting patients.
|
Purpose
OBJECTIVES: I. Compare the resting energy expenditure using respiratory calorimetry in infants and children with moderate to severe cystic fibrosis versus age matched healthy controls. II. Determine the total energy expenditure and energy spent on physical activity using the doubly labeled water method in these patient populations.
| Condition |
|---|
| Cystic Fibrosis |
MedlinePlus related topics: Cystic Fibrosis
Genetics Home Reference related topics: cystic fibrosis
Study Type: Observational
Study Design: Natural History
Expected Total Enrollment: 60
Study start: June 1996
PROTOCOL OUTLINE: Patients and healthy controls receive an oral dose of doubly labeled water following initial urine collection on day 1. Patients undergo additional urine collection at 4-6 hours following doubly labeled water consumption and then daily for 7 days. Additionally, at the beginning of the study, patients and healthy controls undergo respiratory calorimetry over approximately 45 minutes at rest, starting approximately 2-3 hours after the last meal consumption and last use of aerosol bronchodilators (if required).
Eligibility
Ages Eligible for Study: up to 10 Years, Genders Eligible for Study: Both
Accepts Healthy Volunteers
Criteria
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
- Diagnosis of cystic fibrosis (CF) by two positive sweat tests No exacerbations of present condition within past 2 months FEV1 less than 50% of predicted No other uncorrected lung disease No requirement for supplemental oxygen
OR
- Healthy (control group) Age matched to CF patients No preexisting lung disease Clinically well No hospitalizations within past 6 months
--Prior/Concurrent Therapy--
- Concurrent pancreatic enzyme supplementation for CF required Clinically stable on current medications (CF patients)
--Patient Characteristics--
- Age: Birth to 12 months 6 to 10 years
- Cardiovascular: No major cardiovascular problems (CF patients) No preexisting heart disease (control group)
- Pulmonary: See Disease Characteristics
- Other: No chromosomal abnormalities (CF patients) No acute infection (CF patients) No diabetes mellitus (both groups)
Location and Contact Information
Indiana
Indiana University, Indianapolis, Indiana, 46202-5167, United States; Recruiting
Catherine A. Leitch, Study Chair, Indiana University
More Information
Record last reviewed: December 2003
Last Updated: October 13, 2004
Record first received: September 11, 2000
ClinicalTrials.gov Identifier: NCT00006273
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005

Not Signed In -


